Discovery of potent CCR4 antagonists: Synthesis and structure–activity relationship study of 2,4-diaminoquinazolines
摘要:
A new series of quinazolines that function as CCR4 antagonists were discovered during the screening of our corporate compound libraries. Subsequent compound optimization elucidated the structure-activity relationships and led the identification of 2-(1,4'-bipiperidine-10-yl)-N-cycloheptyl-6,7-dimethoxyquinazolin-4- amine 14a, which showed potent inhibition in the [S-35] GTPcS-binding assay (IC50 = 18 nM). This compound also inhibited the chemotaxis of human and mouse CCR4-expressing cells ( IC50 = 140 nM, 39 nM). (c) 2008 Elsevier Ltd. All rights reserved.
Discovery of potent CCR4 antagonists: Synthesis and structure–activity relationship study of 2,4-diaminoquinazolines
摘要:
A new series of quinazolines that function as CCR4 antagonists were discovered during the screening of our corporate compound libraries. Subsequent compound optimization elucidated the structure-activity relationships and led the identification of 2-(1,4'-bipiperidine-10-yl)-N-cycloheptyl-6,7-dimethoxyquinazolin-4- amine 14a, which showed potent inhibition in the [S-35] GTPcS-binding assay (IC50 = 18 nM). This compound also inhibited the chemotaxis of human and mouse CCR4-expressing cells ( IC50 = 140 nM, 39 nM). (c) 2008 Elsevier Ltd. All rights reserved.
[EN] TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE MÉTHYLTRANSFÉRASES
申请人:GLOBAL BLOOD THERAPEUTICS INC
公开号:WO2019036377A1
公开(公告)日:2019-02-21
The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
申请人:Korea Research Institute Of Chemical Technology
公开号:EP2089354A1
公开(公告)日:2009-08-19
TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS
申请人:Global Blood Therapeutics, Inc.
公开号:EP3668863A1
公开(公告)日:2020-06-24
[EN] NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] DÉRIVÉS DE NAPHTHALÉNYLOXYPROPÉNYLE AYANT UNE ACTIVITÉ INHIBITRICE ENVERS L'HISTONE DÉSACÉTYLASE ET UNE COMPOSITION PHARMACEUTIQUE CONTENANT CEUX-CI
申请人:KOREA RES INST CHEM TECH
公开号:WO2008054154A1
公开(公告)日:2008-05-08
[EN] The present invention discloses novel naphthalenyloxypropenyl derivatives useful for inhibiting the enzyme activity of histone deacetylase, leading effective suppression of cancer cell proliferation. [FR] L'invention concerne de nouveaux dérivés naphthalényloxypropényle utiles pour inhiber l'activité enzymatique de l'histone désacétylase, conduisant à la suppression efficace de la prolifération de cellules cancéreuses.
Discovery of potent CCR4 antagonists: Synthesis and structure–activity relationship study of 2,4-diaminoquinazolines
A new series of quinazolines that function as CCR4 antagonists were discovered during the screening of our corporate compound libraries. Subsequent compound optimization elucidated the structure-activity relationships and led the identification of 2-(1,4'-bipiperidine-10-yl)-N-cycloheptyl-6,7-dimethoxyquinazolin-4- amine 14a, which showed potent inhibition in the [S-35] GTPcS-binding assay (IC50 = 18 nM). This compound also inhibited the chemotaxis of human and mouse CCR4-expressing cells ( IC50 = 140 nM, 39 nM). (c) 2008 Elsevier Ltd. All rights reserved.